

Annexe 0

Bibliography

February 2007

OFT885o

© **Crown copyright 2007**

This publication (excluding the OFT logo) may be reproduced free of charge in any format or medium provided that it is reproduced accurately and not used in a misleading context. The material must be acknowledged as crown copyright and the title of the publication specified.

Bibliography

3T study (2003), *Clinical Therapy*, 25.

Abacus Study (2005), *'NICE guidance, implementation tracking, data sources, methodology and results'*

Äbelö et al (2000), *'Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes'*, *Drug Metabolism and Deposition*, 28.

ABPI proposal, 27 May 2004

Accountability and Management, February, 13:1

Adams, C.P and Brantner, V.V., (2006) *'Estimating The Cost Of New Drug Development: Is It Really \$802 Million?'* *Health Affairs*, 25, 420-428.

Adria-Wien Pipeline GmbH (Case143/99, [2002] ECR I-8365

Adria-Wien Pipeline GmbH, C-379/98, C-143/99

Agusti et al (2003), *'Adverse Effects of ACE Inhibitors in Patients with Chronic Heart Failure and/or Ventricular Dysfunction: Meta-Analysis of Randomised Clinical Trials'*, *Drug Safety*, 26.

Ai, C. and Sappington, D (2002), *'The Impact of State Incentive Regulation on the U.S. Telecommunications Industry'*, *Journal of Regulatory Economics*, 22:2.

Allen and Harkins (2005), *Lancet*, (365), p1768

Article 100 of Law 25/1990 (Ley del Medicamento)

Audit Commission (2005), *'Managing the financial implications of NICE guidance'*, Audit Commission report.

Auquier, Robitail et al (2003), *'Comparison of escitalopram and citalopram efficacy: A meta analysis'*, *International Journal of Psychiatry in Clinical Practice*, 7.

Australian Government (2006), Department of Health and Ageing, November, *'Strengthening your PBS – Preparing for the future'*

Averch and Johnson (1962), *'Behaviour of the Firm under Regulatory Constraint'*, *American Economic Review*, 52:5.

Bank of England (2005), *'Determination of UK Corporate Capital Gearing'*, Bank of England Quarterly Bulletin Autumn.

- Baron, D (1995), *'Integrated strategy; market and non-market components'*, California Management Review, 37 (2), 47-65.
- Berndt and Danzon (2006), *'Dynamic Competition in Pharmaceuticals: Cross-National Evidence from New Drug Diffusion'*, Working Paper.
- Bloom, N, Schankerman, M and Van Reenen, J (2005), *'Identifying Technology Spillovers and Product Market Rivalry'*, CEPR Discussion Papers 4912.
- Bloom, N. and Van Reenen, J (1998), *'Regulating Drug Prices: Where do We Go from Here?'*, Fiscal Studies, 19.3
- Borrell, J.R (1999), *'Pharmaceutical Price Regulation: A Study on the Impact of the Rate-of-Return Regulation in the UK'*, Pharmacoeconomics, 19.3 March.
- Brander (1995), *'Strategic Trade Policy'*, Chapter 27 in Gene Grossman and Kenneth Rogoff (ed.) Handbook of International Economics, Vol. III (elsevier: Amsterdam). pp. 1395-1455
- Brander and Spencer (1985), *'Export subsidies and international market share rivalry'*, Journal of International Economics 18
- Brealey, R.A., Myers S.C. and Allen, F (2006), *Corporate Finance (eighth edition)*, McGraw Hill,
- Burstall, M.L (1997), *'How do they do it elsewhere in Europe?'*, in D. Green (1997), *'Should Pharmaceutical Prices be Regulated?'*, London: Institute of Economic Affairs.
- Canadian Institute for Health Information (CIHI), *Drug Expenditure in Canada, 1985 – 2005*.
- CAPDM (2005), *CAPDM Industry Trends Report 2005 Pharmacy Distribution*, Spring.
- CAPRIE (1996), trial found in London New Drugs Group in February 2003 and NICE TA90 dated May 2005.
- Carltona Ltd. v Commissioners of Works [1943] 2All ER 540.
- Chapman et al (2003), *'Setting up an outcomes guarantee for pharmaceuticals: a new approach to risk sharing in primary care'*, BMJ.
- CHMP Guideline on similar biological products (CHMP/437/04)
- CHMP Note for Guidance on the Investigation of bioavailability and bioequivalence, (CPMP/EWP/QWP/1401/98)
- Clark and MacDonald (1999), *'Exchange Rates and Economic Fundamentals: A Methodological Comparison of BEERs and FEERs'* in MacDonald and Stein (eds), Equilibrium Exchange Rates, Kluwer.

Clark and West (2005), *'Using out-of-sample Mean Squared Prediction Errors to Test the Martingale Difference Hypothesis'*, Journal of Econometrics, 135.

Colonna (2005), *'A randomized, double-blind 24 week study of escitalopram (10mg/day) versus citalopram (20mg/day) in primary care patients with major depressive disorder'*, Current Medical Research and Opinion, 21.

Commercial Solvents Cases C-6/73

Commission Decision 2001/791/EC

Commission Decision 2006/857/EC – CFI case T-321/05 challenge

Commission Decision 92/327/EEC, OJ 1992 L182/89

Commission v Austria, ECJ C-424/99

Commission v Belgium (Case 249/88, [1991] ECR I 1275)

Commission v Belgium Case 249/88, [1991] ECR I 1275

Commission v Finland Case C-229/00.

Commission v Italy (Case 56/87, [1988] ECR 2919)

Commission v Italy, Case 56/87, [1988] ECR 2919

Competition Act 1998

Competition Commission (2000), *'New Cars: A Report on the Supply of New Motor Cars within the UK'*, April.

Competition Commission (2002), *'The Supply of Banking Services to Small and Medium Sized Enterprises'*, March.

Congress Budget Office (2007), *'Prescription Drug Pricing in the Private Sector'*, CBO January.

Cookson, R, McDaid D, Maynard A. (2001), *'Wrong SIGN, NICE mess: is national guidance distorting allocation of resources?'*, BMJ, 323:743-745.

Cools, M, and Emmanuel, C (2006), *'Transfer pricing; the implications of fiscal compliance'* in Chapman, Hopwood, A C and Shields, M, *'Handbook of Management Accounting Research'*, Elsevier, chapter 5 vol. 2, 579-591.

Cools, M, Emmanuel, C and Jorissen, A (2006), *'Management control system design and use in the transfer pricing tax compliant multinational enterprise'*, working paper series, University of Glasgow.

CURE Study found in Midlands Therapeutic Review and Advisory Committee (MTRAC) in October 2002 NICE Technology Appraisal TA80 dated June 2004 and Yusuf et al (2001), *'Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation'*, New England Journal of Medicine, 345.

Danzon P and Furukawa, M (2003), *'Prices and availability of pharmaceuticals: Evidence from nine countries'*, Health Affairs Web Exclusive, October;

Danzon, P (1997), *'Price Discrimination for Pharmaceuticals: Welfare Effects in the US and EU Industry'*, International Journal of the Economics of Business, Vol 4, No 3, 1997.

Danzon, P and Percy, A (1995) *'The Effects of Price Regulation on Productivity in Pharmaceuticals'*.

Danzon, P, Chao, L (2000), *'Cross-national price differences for pharmaceuticals: how large, and why?'*, Journal of Health Economics 19, 159-195.

Danzon, P. (1997), *'Price Discrimination for Pharmaceuticals: Welfare Effects in the US and EU Industry'*, International Journal of the Economics of Business, Vol 4, No 3, 1997

Danzon, P. and Keufel, E (2005), *'Regulation of the Pharmaceutical Industry'*, paper prepared for NBER Conference on Regulation, September.

Datamonitor (2003), *'Pharmaceutical Reimbursement Strategies: Maximising Revenue Potential in Europe, US and Japan'*, June.

de Wolf, P, Brouwer, W B F and Rutten, F F H (2005), *'Regulating the Dutch pharmaceutical market: improving efficiency or controlling costs?'*, International Journal of Health Planning and Management, 20, 351-374.

Department of Health (1993), *'Pharmaceutical Price Regulation Scheme'*, October.

Department of Health (1996), *'Pharmaceutical Price Regulation Scheme: First Report to Parliament'*

Department of Health (1999), *'Pharmaceutical Price Regulation Scheme'*, July.

Department of Health (2004), *'Pharmaceutical Price Regulation Scheme'*, November.

Department of Health (2005), *'Pharmaceutical Price Regulation Scheme; Eighth Report to Parliament'*, page 24.

Department of Health (2006), *'Pharmaceutical Price Regulation Scheme, Ninth Report to Parliament'*, July.

Department of Health News Release (2006/0314), 20 Sept 2006.

Department of Health *'NHS organisations forecast surplus and deficits 2005-06: Month 6'*

Department of Health *'Prescriptions dispensed in the community: Statistics for 1994 to 2005 – England'*;

Department of Health/ABPI (2002), *'PPRS: The Study into the Extent of Competition in the Supply of Branded Medicines to the NHS'*.

Department of Health(2000), National Service Framework on coronary heart disease

Devlin N and Parkin D (2004), *'Does NICE have a cost effectiveness threshold and what other factors influence its decisions? A binary choice analysis'*, Health Economics, (13).

Di Masi, J, Hansen, R. and Grabowski, H. (2003) *'The Price of Innovation: New Estimates of Drug Development Costs'*, Journal of Health Economics, 22, 151–85.

Di Masi, J.A (1995), *'Success Rates for New Drugs Entering Clinical Testing in the United States'*, Clinical Pharmacology and Therapeutics, 58:1.

DiMasi, J.A., Hansen, R.W. and Grabowski H.G., (2005), *'Reply to Light and Warburton: Extraordinary claims require extraordinary evidence'*, Journal of Health Economics, 24, 1034-1044.

DiMasi, J.A., Hansen, R.W., Grabowski H.G.,and Lasagna, L., (1991), *'Cost of innovation in the pharmaceutical industry'*, Journal of Health Economics, 10, 107-142.

Directive 2001/83/EEC

Drug Tariff for England and Wales, Part XVIII C.

Dunning, J (1980), *'Toward an eclectic theory of international production: some empirical tests'*. Journal of International Business Studies, 11, 9-31.

Durst, M (2002), *'Management versus tax accounting in intercompant transfer pricing'*, Tax Management International Journal, 31 (2), 95-103.

Earl-Slater, A (1997), *'The Pharmaceutical Price Regulation Scheme'*, Financial Times

EC Treaty, Articles: 28, 30, 81, 82, 87, 234

Eden, L (1998), *'Taxing multinationals; transfer pricing and corporate income taxation in North America'*, Toronto, University of Toronto Press.

Enemardk, U, Moller, K and Sorensen, J (2006), *'The economic impact of parallel import of pharmaceuticals'*, Centre for Applied Health Services Research and Technology Assessment, University of Southern Denmark, June.

Ernst and Young (2005), Global transfer pricing surveys, <http://www.ey.com/global>.

European Federation of Pharmaceutical Industries Association, Annual report 2004

Federation of Icelandic Trade v Iceland, EFTA E-2/98

Fischer, Scherngell and Jansenberger (2004) *'The geography of knowledge spillovers between high technology firms in Europe – Evidence from a spacial interaction modelling perspective'*. 45th Congress of the European Regional Science Association, 23 – 27 August.

Fraser Group/ Tristat Resources, (2002), *Drug expense coverage in the Canadian population: protection from severe drug expenses*

Glaxosmithkline SA v Belgium, ECJ C-296/03

GlaxoSmithKline Services Unlimited v Commission of the European Com, Case CJE/06/79 - Judgment of the Court of First Instance in Case T-168/01

GlaxoSmithKline Services Unlimited v Commission, CFI Case T-168/01

Government of Wales Act 1998

Grabowski, H (2006), *Competition between innovative and generic drugs: The US Experience and Current Policy Issues*, OHE Seminar.

Grabowski, H and Vernon, J (1994), *'Returns on Research and Development for New Drug Introductions in the 1980s'*, Journal of Health Economics 13(4) 383-406

Grabowski, H, and Vernon, J (2000), *'The Distribution of Sales Revenue from Pharmaceutical Innovation'*, Pharmacoeconomics, 18:,1, 21-32.

Grabowski, H, Vernon, J. and DiMasi J.A (2002), *'Returns on Research and Development for 1990s New Drug Introductions'*, Pharmacoeconomics, 20, Supplement 3, 11–19.

Graham, J, and Harvey, C (2001), *'The Theory and Practice of Corporate Finance: Evidence from the Field'*, Journal of Financial Economics, 61.

Green, D. (ed), (1997), *'Should Pharmaceutical Prices be Regulated?'*, London: Institute of Economic Affairs.

Grenadier, S (2002), *'Option Exercise Games: An Application to the Equilibrium Investment Strategies of Firms'*, The Review of Financial Studies, 15, 691–721.

Gresik, T (2001), *'The Taxing Task of Taxing Transnationals'*, Journal of Economic Literature, 39, September, 800–38.

Griliches, Z (1992), *'The Search for R & D Spillovers'*, National Bureau of Economic Research Working Papers 3768.

Grossman, G. M. and Lai, E. L.C., (2006) *'Parallel Imports and Price Controls'* NBER Working Paper No. W12423 August.

Grubert, H, Goodpeed, T and Sivenson, D (1993), *'Explaining the low taxable income of foreign controlled companies in the United States'* in Giovanni, A, Hubbard, G and Slemrod, J *'Studies in International Taxation'*, National Bureau of Economic Research Project Report, University of Chicago Press.

Harris, D., Morck, R. Slemrod, J. and Yeung, B (1993), *'Income Shifting in US Multinational Corporations'* in Giovannini, A., Hubbard, G. and Slemrod J, *'Studies in International Taxation'*, Chicago and London: University of Chicago Press.

Healey, P., Myers, S.C. and Howe, C.D. (1999), *'R&D Accounting and the Tradeoff between Relevance and Objectivity'*, mimeo.

Health Act 1999, Sections 33-38.

Health Select Committee Report 2004-05 on the influence of the pharmaceutical industry in www.parliament.uk

Health Service Medicines (Consent to Voluntary Scheme) Regulations 1999.

Health Service Medicines (Control of Prices of Branded Medicines) Regulations 2000

Health Service Medicines (Control of Prices of Specified Generic Medicines) Regulations 2000.

Health Service Medicines (Information on the Prices of Specified Generic Medicines) Regulations 2001.

Health Service Medicines (Price Control Appeals) Regulations 2000.

Healthcare Commission report, (2006), *'Results of the annual health check 2005/2006'*

Hill S, Garattini S, van Loenhout J, O'Brien B, de Joncheere K (2003), *Technology appraisal programme of the National Institute for Clinical Excellence: a review by the WHO*. London.

HM Revenue and Customs,(2005), *'R&D tax Credits Final Report December 2005'*

HM Treasury (1997) *'Appraisal and Evaluation in Central Government'*

HM Treasury, (2004) *'Science and Innovation Investment Framework 2004-2014'*

HM Treasury's Cooksey Review, July (2006), '*Review of UK Health Research Funding*'

House of Commons Health Committee, (2002) '*Review of the National Institute for Clinical Excellence, London, Stationery Office*'

HPS study (2002), Lancet, 360.

HTA Report, (2001), '*Guidance on drugs for Alzheimer's disease*'

IASB (2006), '*Fair value measurement guidance*, July 2006. www.iasb.org

Implementation of NICE Guidance on use of anti-TNF therapies for adults with rheumatoid arthritis (2005), British Society for Rheumatology and the Arthritis & Musculoskeletal Alliance.

'*Improving Health Care: A Dose of Competition*' (2004), A Report by the Federal Trade Commission and the Department of Justice, July.

IMS '*Global Pharmaceutical Perspectives 2005*'.

IMS, '*Global Pharmaceutical Perspectives 2004*'.

IMS, '*Global Pharmaceutical Perspectives 2006*', IMS Health Total Market Estimates and Global Pharma Forecasts (Includes IMS Audited and Unaudited Markets).

Jacob, J (1996), '*Taxes and Transfer Pricing: Income Shifting and the Volume of Intrafirm Transfers*', Journal of Accounting Research, 34:2.

Jaffe, A B, Trajtenberg, M and Henderson, R (1993), '*Geographic Localization of Knowledge Spillovers as Evidenced by Patent Citations*', National Bureau of Economic Research Working Papers 3993.

Jamasb, T and Pollitt, M (2005), '*Deregulation and R&D in Network Industries: The Case of the Electricity Industry*', CWP3 0533 and EPRG 02, Working Paper, August.

Kahrilas et al (2000), '*Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial*', Alimentary Pharmacology and Therapeutics, 14.

Kanavos P, Costa-Font J and Jönsson B, (2007) '*Explaining Cross-Country Drug Price Differences: What is the value of innovation?*', LSE Health Discussion, Paper, forthcoming;

Kanavos, Gross, Taylor (2005), '*Parallel trading in medicines: Europe's experience and its implications for commercial drug importation in the United States*', Juen, AARP Public Policy Institute

Kanavos, P, Costa-Font, J, Merkur, S and Gemmil, M (2004) *'The economic impact of pharmaceutical parallel trade in European Union Member States: a stakeholder analysis'*, LSE Special Research Paper, January.

Kanavos, P. and Costa-Font, J (2005), *'Pharmaceutical parallel trade in Europe: stakeholder and competition effects'*, Economic Policy October, 751-798.

Kanavos, P., Gross, D. and Taylor, D (2005), *'Parallel Trading in Medicines: Europe's Experience and Its Implications for Commercial Drug Importation in the United States'*, AARP Public Policy Institute.

Kaplan, (2000) *'Mergers and Productivity'*, 313

Kilian and Taylor (2003), *'Why is it so difficult to beat the random walk forecast of exchange rates?'*, Journal of International Economics, 60.

King's Fund (2006), *'Local variations in NHS spending priorities'*.

Klopfer, J., Peters, D. and Waldens, S (2005), *'The Challenge to Align Operational and Legal Transfer Pricing'*, International Tax Review, July.

KPMG's Corporate Tax Rate Survey (2005).

Kraus, A. and Litzenberger, R (1976), *'Skewness Preference and the Valuation of Risk Assets'*, The Journal of Finance, XXXI:4, September.

Langli, J and Saudagaran, S (2004), *'Taxable income differences between foreign and domestic controlled corporations in Norway'*, European Accounting Review, 13(4), 713-741

Lanjouw (2005), *'Patents, price controls and access to new drugs: how policy affects global market entry'*, prepared for the Commission on Intellectual Property Rights, Innovation, and Public Health of the World Health Organization.

Leahy and Neary, (2000) *'Robust rules for Industrial policy in open economies'*, Journal of International Trade and Economic Development

Leitch, R and Barrett, K (1992), *'Multinational transfer pricing: objectives and constraints'*, Journal of Accounting Literature, 11, 47-92.

Ley 25/1990, of 20 December (1990), Titulo VIII, Article 100(2), *'El Ministerio de Sanidad y Consumo, ..., establecerá el precio industrial máximo con carácter nacional, para cada especialidad farmacéutica ...'*.

Ley 29/2006 of 26 July (2006), Article 87 *'Garantías de trazabilidad'*;

Light, D. W. and Warburton, R.N. (2005), '*Extraordinary claims require extraordinary evidence*', *Journal of Health Economics*, 24, 1030-1033.

Lin, C, Lefebvre, C and Kantor, J (1993), '*Economic determinants of international transfer pricing and the related accounting issues with particular reference to Asian Pacific countries*', *International Journal of Accounting*, 28 (1), 49-70.

Luffman J. (2005), '*Out-of-pocket spending on prescription drugs, Perspectives on Labour and Income*', Vol. 17, No. 4, pp 5-13.

Maynard, A. and Bloor, K (1997), '*Regulating the Pharmaceutical Sector*', *British Medical Journal*, 315, 200–1.

Medicines (Advertising) Regulations 1994, Regulation 21(I) and (3) and Regulation 23(1) and (2)

Mehafdi, M (2000), '*The ethics of international transfer pricing*', *Journal of Business Ethics*, 28 (4), 365-381.

Merchant, K (1989), '*Rewarding Results: motivating profit center managers*', Harvard Business School Press, Boston Massachusetts.

Merck, Sharp & Dohme BV v Belgium, ECJ C-245/03

Miners AH, Garau M, Fidan D, Fischer AJ. (2005) '*Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study*'. *BMJ* 2005;330:65-68.

Monopolies and Mergers Commission (1992), '*New Motor Cars: A Report on the Supply of New Motor Cars within the United Kingdom*', February.

Moore, Verdoux et al (2005), '*Prospective, multi-centre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder*', *International Clinical Psychopharmacology*, 20.

Mossialos, E (1997), '*An Evaluation of the PPRS: Is there a Need for Reform?*', in Green, D (1997), '*Should Pharmaceutical Prices be Regulated?*', London: Institute of Economic Affairs.

Mudher and Lovestone (2002), '*Alzheimer's disease: do tauists and baptists finally shake hands?*', *Trends in Neuroscience*.

Myers, S.C. and Howe, C.D (1997), '*A Life-cycle Financial Model of Pharmaceutical R&D*', Working Paper, Program on the Pharmaceutical Industry, Massachusetts Institute of Technology, Cambridge, MA.

Myers, S.C. and Shyam-Sunder, L (1996) '*Cost of Capital Estimates for Pharmaceutical Research and Development*', in R. M. Helms, '*Competitive Strategies in the Pharmaceutical Industry*', Washington DC: American Economic Institute.

Nadiri, M I (1993) '*Innovations and Technological Spillovers*', National Bureau of Economic Research Working Papers 4423.

Napp Pharmaceutical Holdings Limited and Subsidiaries. Decision of the Director General of Fair Trading No CA98/2/2001, 30 March 2001,

National Assembly for Wales (Transfer of Functions) Order 1999, Article 2, Schedule 1 (made under Government of Wales Act 1998)

National Audit Office Wales, (2003) '*The procurement of primary care medicines*' – Report by the National Audit Office Wales on behalf of the Auditor General for Wales, March.

National Health Service (General Medical Services Contracts) (Prescription of Drugs etc.) Regulations 2004, SI 2004/629, which applies only to England

National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) Regulations 2004, SI 2004/1022, which applies only to Wales

National Health Service (Pharmaceutical Services) (Scotland) Regulations 1995, Regulation 9 (made under S.27 of NHS (Scotland) Act 1978

National Health Service (Pharmaceutical Services) Regulations 1992, Regulation 18 (1), 1992/662

National Health Service (Pharmaceutical Services) Regulations 2005, Regulation 56 (1) 2005/641 and Paragraph 3 of Schedule II.

National Health Service (Scotland) Act 1978

National Health Service (Wales) Act 2006

National Health Service Act 1977, S. 2; S.11; S.16(2); S.124(4); S.126(4); S.11; S.42, Schedule 6.

National Health Service Act 2006, S.28; Ss 260 – 268; Ss 271 (3) and 278(3)

National Health Service Health Department Letter (NHS HDL) (2003) 60 of 25 November

National Health Service Health Department Letter (NHS HDL) (2006) 29 of 12 May

National Institute for Clinical Excellence (Establishment and Constitution) Order 1999, Article 3

National Institute for Clinical Excellence (Establishment and Constitution) Amendment Order 2005.

NERA report and Charles River Associates, (2004) *'Innovation in the Pharmaceutical Sector: A Study undertaken for the European Commission'*

NICE 2004, *'Guide to the Methods of Technology Appraisal'*.

NICE, *'Clinical and cost effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease'*, NICE Health Technology Appraisal TA091.

NICE, (2004), *'Managing dyspepsia in adults in primary care'*, NICE's Clinical Guideline 17, August.

NICE's TA77 *'Insomnia – Newer Hypnotic Drugs'*

Nick Bloom, Rachel Griffith, John Van Reenen, (2002), *'Do R&D tax credits work? Evidence from an international panel of countries 1979-1994'* Institute of Fiscal Studies.

Northern Ireland Act 1998

OECD (1995) Transfer pricing guidelines for multinational enterprises and tax administrations, <http://www.oecd.org>

OECD Health Data 2005.

Ofcom (2004), *'Wholesale Mobile Voice Call Termination'*, statement, June 1st.

Ofcom (2005), *'Ofcom's Approach to Risk in the Assessment of the Cost of Capital, January'*.

Office of Fair Trading (2003), *'The control of entry regulations and retail pharmacy services in the UK'*, OFT Report No. 609, London.

Office of Fair Trading study, (2004) *'Assessing the impact of public sector procurement on competition'*

Office of Health Economics, (2002) *'Influencing Prescribing in a Primary Care Led NHS: A Review of the Management of Prescribing and Findings from the MANMED Survey'*

Oftel (1998), *'Conditional Access Charges for Digital Television'*, February.

Ofwat (2005), *'Regulatory Accounting Guideline v.5.04'*, March.

Opinion on Pharmacotherapy, Vol 7, No.4, March, 429 – 440, Informa Healthcare.

Os and Stokke (1999), 'Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension', *Journal of Cardiovascular Pharmacology*, 33.

Oxera (2003), '*Assessing Profitability in Competition Analysis*', July.

Oyelere, P and Emmanuel, C (1998), '*International transfer pricing and income shifting; evidence from the UK*', *European Accounting Review*, 7 (4), 623-635.

Pagan, J and Wilkie, S (1993), '*Transfer pricing strategy in a global economy*', International Bureau of Fiscal Documentation, Amsterdam.

Pharmaceutical and Medicaments Price Review Board (2006), *Non-Patented Prescription Drug Prices Reporting Canadian and Foreign Price Trends*, June 2006.

Pharmaceutical Industry Task Force, (2004) '*Clinical Research Report*'

Pharmaceutical Journal, Vol 277 No 7430 p679, 9 December 2006

Pharmaceutical Price Regulation Scheme (2001), *Fourth Report to Parliament*, Department of Health.

Pharmaceutical Price Regulation Scheme (2005) Paragraphs 21.11 and 22.8.

Pharmaceutical Pricing Regulation Scheme 2005

Pharmaceutical Services Regulations (Northern Ireland) 1997, Regulation 9, SR 1997/381

'Pharmacy Benefits Managers: Tools for Managing Drug Benefit Costs, Quality, and Safety' (2003), Pharmaceutical Care Management Association (PCMA).

Picciotto, S (1992), '*International taxation and intrafirm pricing in transnational corporate groups*', *Accounting, Organizations and Society*, 17, 759-792.

Pindyck, R (2004), '*Mandatory Unbundling and Irreversible Investment in Telecom Networks*', NBER Working Paper No. W10287, September.

Porter, M (1985); '*Competitive advantage, creating and sustaining superior performance*', The Free Press, New York, NY.

PPRS: Annual Financial Returns, 2004 found in www.abpi.org.uk.

PPRS: The Study into the Extent of Competition in the Supply of Branded Medicines to the NHS, (2002) DH/ABPI

PreussenElektra AG v. Schleswag AG (Case 379/98, [2001] ECR I-2099)

PreussenElektra AG v. Schleswag AG C-379/98

Prosser and Walley (2005), *'Social Science and Medicine'*, (60), p1335.

R v The Secretary of State for Health ex parte Association of Pharmaceutical Importers, Association of the British Pharmaceutical Industry [2001] EWHC Admin 183

Raftery J, *Review of NICE's recommendations 1999-2005*, BMJ; 332, 2006

Rapport d'activité (2004), Comité Economique des Produits de Santé, juillet.

Redwood, H (1997), *'The PPRS: International Perspectives and Millennial Change'*, in

Reekie. W.D (1997), *'The PPRS: Regulations without a Cause?'*, in Green, D, (1997), *'Should Pharmaceutical Prices be Regulated?'*, London: Institute of Economic Affairs.

Reinhardt, U (2001), *'Perspectives on the Pharmaceutical Industry'*, Health Affairs, 20:5, 141.

Rogoff (1997), *'The Purchasing Power Parity Puzzle'*, Journal of Economic Literature, 34.

Roussel Laboratoria BV v État Néerlandais (Case 181/83, [1983] ECR 3849)

Schedule of Pharmaceutical Benefits, August 2006, 74.

Scherer, F. M (2001), *'The Link Between Gross Profitability and Pharmaceuticals R&D Spending'*, Health Affairs, 20, 216-220.

Scholes, M and Wolfson, M (1992), *'Taxes and business strategy; a planning approach, Prentice Hall'*.

Schwabe, U and Paffrath, D, (2006), *Arzneiverordnungs Report*, Springer

Schwartz, E.S (2004), *'Patents and R&D as Real Options'*, Economic Notes by Banca Monte dei Paschi di Siena SpA, 33:1.

Scotland Act 1998, Ss 29, 30, and J4 of Part II to Schedule 5.

Scrip magazine (2006), *'Parallel traders get smarter in declining market'*, May.

Sheldon TA, Cullum N, Dawson D, et al. *'What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes and interviews'*, BMJ, 2004; 329:999-1006.

Shoup, C (1985), *'International arbitration of transfer pricing disputes under income taxation'*, in A.Rugman and L. Eden, *'Multinationals and transfer pricing'*, London and New York, St Martin's Press and Croom Helm, 291-309.

Skinner, B, *'Price Controls, Patents and Cross-Border Internet Pharmacies'*. in <http://www.fraserinstitute.ca/admin/books/files/PriceControls&XborderPharmacies1.pdf>

Smith, R. (2000) *The failings of NICE*, *BMJ*, 321:1363-1364. Cookson.

Social Value Judgements: Principles for the development of NICE guidance, December 2005.

Spending Review, July.

Spicer, B (1988), *'Towards an organizational theory of the transfer pricing process'*, *Accounting, Organizations and Society*, 13, 303-322.

'Statins for the prevention of cardiovascular disease' (2006), NICE Technology Appraisal TA94, January.

Stichting Farmaceutische Kengetallen, Ministerie van Volksgezondheit, Welzijn an Sport, (study comissioned by the Dutch Ministry of Health, Wellbeing and Sport), www.sfk.nl

Sudlow and Counsell (2003), *'Problems with the UK government's risk sharing scheme for assessing drugs for multiple sclerosis'*, *BMJ*.

Syfait and others v. Glaxosmithkline A EVE, ECJ Case C-53/03

Synetairismos Farmakopoion Aitolias & Akarnanias (Syfait) and Others v Glaxosmithkline A EVE, Advocate General's Opinion in Case C-53/03.

Tepea v Commission, Case C-28/77

Thase (2006), *'Managing depressive and anxiety disorders with escitalopram'*, Expert

Tischendorf, A (AT Kearney) and Nusser, M (2005), *'The Research Based Pharmaceutical Industry as a Chance for the Business Location Germany'*.

Touche and Tohmatsu (2004), *'The strategic matrix for global transfer pricing'*, London, Deloitte.

Transparency Directive 89/105/EEC, Articles 1 – 11.

Tucker (2000), *'Chiral switches'*, *Lancet* 355.

UK (R (on the application of Pfizer Ltd.)) v. Secretary of State for Health [2003] 1 CMLR 19

UK Inland Revenue (1998) Section 770 and Schedule 28AA Taxes Act of 1998. London, Inland Revenue.

UKTI and ABPI, (2006) *'Key Factors in Attracting Internationally Mobile Investments by the Research-Based Pharmaceutical Industry'*, November

United Brands C-27/76

US Internal Revenue Service (1994), *Intercompany transfer Pricing Regulations under section 482. TD 8552 (482-F94)*, Washington, Government Printing Office.

Van Reenen (1998) *Econometric analysis of data from the Labour Force Survey*.

West, P. and Mahon, J (2003), *'Benefits to Payers and Patients from Parallel Trade'*,

WHO (2004), *'Priority medicines for Europe and the world'*, Department of Essential Drugs and Medicines policy, document WHO/EDM/PAR/2004.7.

WHO (2004), *'Priority medicines for Europe and the world'*, Department of Essential Drugs and Medicines policy, document WHO/EDM/PAR/2004.7.

Williams, A (2004) *'What could be nicer than NICE?'*, Office of Health Economics.

Williamson, O E (1979), *'Transaction cost economics: the governance of transactional relations'*, *Journal of Law and Economics*, 22, 3-61.

Wren-Lewis (2003), *'Estimates of equilibrium exchange rates for sterling against the euro'*, HM Treasury.

York Health Economics Consortium (2003), *'Benefits to Payers and Patients From Parallel Trade'*, May 2003

York Health Economics Consortium (2003), *'Benefits to Payers and Patients from Parallel Trade'*, (report for the European Association of Euro-pharmaceutical companies), May.

York Health Economics Consortium, York, May, <http://www.yhec.co.uk>.

Websites:

http://www.abpi.org.uk/amric/tried_&_tested.pdf.

<http://afssaps-prd.afssaps.fr/html/has/sgt/>, avis de la Commission de 13 octobre 2004.

<http://data.euro.who.int/hfadb/>

http://ec.europa.eu/comm/competition/state_aid/reform/rdi_en.pdf

http://ec.europa.eu/comm/competition/state_aid/reform/rdi_en.pdf

<http://europa.eu.int/>

<http://europa.eu/rapid/pressReleasesAction.do?reference=IP/05/737&format=HTML&aged=1&language=EN&guiLanguage=fr>

<http://www.abpi.org.uk>

<http://www.advisorybodies.doh.gov.uk/pictf/publications.htm>.

http://www.aponet.de/apotheke/ampreise/07_03_02_00_00_c_AMpreise_ebau.html

<http://www.audit-scotland.gov.uk/publications/audithealth05.htm>.

http://www.canadiangenerics.ca/en/resource/market_trends.shtml

http://www.capdm.ca/industry_facts/facts.asp

<http://www.catribunal.org.uk/documents/JdgNapp150102.pdf>

http://www.cms.hhs.gov/mcd/ncpc_view_document.asp?id=10

<http://www.cms.hhs.gov/NationalHealthExpendData>

<http://www.dh.gov.uk/assetRoot/04/13/71/36/04137136.pdf>

http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsLegislation/PublicationsLegislationArticle/fs/en?CONTENT_ID=4083088&chk=ouBgzM

<http://www.dimdi.de/static/en/amg/fbag/index.htm>.

<http://www.doingbusiness.org>

<http://www.druginfozone.nhs.uk>

<http://www.dti.gov.uk/bbf/state-aid/index.html>

<http://www.euroqol.org>.

<http://www.fda.gov/cder/rdmt/pstable.htm>.

<http://www.keele.ac.uk/depts/mm/MTRAC/>

<http://www.kpmg.com.om>

http://www.lmi.no/Prisrapport%202006_h9tQk.pdf.file.

http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&dID=17736&noSaveAs=0&Rendition=WEB See in particular paragraphs 6.14 to 6.17

http://www.nhshealthquality.org/nhsqis/qis_display.jsp?pContentID=1895&p_applic=CCC&pElementID=260&pMenuID=141&p_service=Content.show&

<http://www.nice.org.uk> (NICE technology appraisal process)

<http://www.nice.org.uk/page.aspx?o=202425>

http://www.nihr.ac.uk/infrastructure_technology_platforms.aspx

[http://www.offt.gov.uk/Business/Competition + Act/Decisions/Napp + Pharmaceutical + Holdings + Limited.htm](http://www.offt.gov.uk/Business/Competition+Act/Decisions/Napp+Pharmaceutical+Holdings+Limited.htm)

<http://www.opsi.gov.uk/acts/en1999/1999en08.htm>

<http://www.opsi.gov.uk/legislation/>

<http://www.parliament.uk>

http://www.pfizer.com/pfizer/download/uspi_cardura_xl.pdf

http://www.ppa.org.uk/ppa/edt_intro.htm

http://www.previade.fr/ebn.ebn?pid=23&domain=site&site=6&uid=documentsite_5236&rub=538

<http://www.psn.org.uk>

http://www.rheumatology.org.uk/public_affairs/armabsrtnfsurvey/

<http://www.wales.gov.uk/keypubmrs/content/06-028.pdf>

<http://www.whocc.no>